Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1809

It is urgent to understand the future of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) transmission. We used estimates of seasonality, immunity, and cross-immunity for betacoronaviruses OC43 and HKU1 from time series data from the USA to inform a model of SARS-CoV-2 transmission. We projected that recurrent wintertime outbreaks of SARS-CoV-2 will probably occur after the initial, most severe pandemic wave. Absent other interventions, a key metric for the success of social distancing is whether critical care capacities are exceeded. To avoid this, prolonged or intermittent social distancing may be necessary into 2022. Additional interventions, including expanded critical care capacity and an effective therapeutic, would improve the success of intermittent distancing and hasten the acquisition of herd immunity. Longitudinal serological studies are urgently needed to determine the extent and duration of immunity to SARS-CoV-2. Even in the event of apparent elimination, SARS-CoV-2 surveillance should be maintained since a resurgence in contagion could be possible as late as 2024.

The ongoing severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) pandemic has caused nearly 500,000 detected cases of coronavirus disease 2019 (COVID-19) illness and claimed over 20,000 lives worldwide as of 26 Mar 2020. Experience from China, Italy, and the United States demonstrates that COVID-19 can overwhelm even the healthcare capacities of well-resourced nations (2–4). With no pharmaceutical treatments available, interventions have focused on contact tracing, quarantine, and social distancing. The required intensity, duration, and urgency of these responses will depend both on how the initial pandemic wave unfolds and on the subsequent transmission dynamics of SARS-CoV-2. During the initial pandemic wave, many countries have adopted social distancing measures, and some, like China, are gradually lifting them after achieving adequate control of transmission.

Read more | >

The widespread perception that it was once official British policy to let the novel coronavirus spread until the population reached herd immunity is false; the government was just overly optimistic about how easy flattening the curve would be. But the idea has gained so much traction in some circles, fueled by speculation that we might already be much closer to it than we think, that it’s worth understanding why it’s not a viable policy according to the evidence to date.

Read more | >

As the world fights against the COVID-19 pandemic, nuclear weapons have taken a backseat in most people’s minds. But for Global Strike Command (AFGSC)—the Air Force unit in control of two of the three legs of America’s nuclear triad—their mission remains top priority.

And it’s an unforgiving business. Nuclear deterrence requires extreme levels of readiness among pilots, maintenance crews, and security teams. Adversaries that don’t think the U.S. can respond with conventional bombing strikes or nukes could be emboldened to act aggressively.

But in a War of the Worlds-style twist, humanity’s most lethal weapons could be nullified by an organism that can’t even be seen. It’s up to the AFGSC to make sure that never happens.

Read more | >

A desirable option would be to use CRISPR gene editing to essentially cut out the unwanted gene. There are, however, many challenges ahead.

If you want to remove an undesirable gene from a population, you have a couple theoretical options — one that most people might find unthinkable, and one that lies outside our current scientific abilities.

The first involves locating a group of people without a particular gene and designing breeding programs around them. It would mean mating people in ways that society would consider incestuous. And we’ve seen the difficulties that result from that in the past — marriages between close relatives were a notorious cause of hemophilia in European royal families, for example.

Continue reading “We can identify ‘bad’ genes. Why can’t we use CRISPR gene editing to get rid of them?” | >

Scientists say they have discovered the first evidence of a “significant” mutation of the coronavirus — raising concerns that strides made toward a vaccine so far could become “futile,” according to a new study.

The researchers, who isolated a strain of the virus from a sample collected in India in January, said the mutation appeared to make the bug less able to bind to a receptor on human cells called ACE2, an enzyme found in the lungs.

The discovery of this mutation “raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified,” the researchers said, according to Newsweek. The study, which was published on biorxiv.org on Saturday, has not yet been peer-reviewed.

Read more | >

More than a century after giving the world aspirin, another potential drug has been found in the stem and leaves of willows—this time with anti-cancer properties.

Scientists led from Rothamsted Research, working with biologists at the University of Kent have discovered the chemical, miyabeacin, which has been found to kill various cancer , including those resistant to other drugs.

Of particular excitement is its activity against neuroblastoma, a hard to treat and common childhood cancer where the overall survival rate is below 50%.

Read more | >